Last reviewed · How we verify
anti-CCR2 monoclonal antibody MLN1202 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
anti-CCR2 monoclonal antibody MLN1202 (anti-CCR2 monoclonal antibody MLN1202) — SWOG Cancer Research Network.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-CCR2 monoclonal antibody MLN1202 TARGET | anti-CCR2 monoclonal antibody MLN1202 | SWOG Cancer Research Network | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-CCR2 monoclonal antibody MLN1202 CI watch — RSS
- anti-CCR2 monoclonal antibody MLN1202 CI watch — Atom
- anti-CCR2 monoclonal antibody MLN1202 CI watch — JSON
- anti-CCR2 monoclonal antibody MLN1202 alone — RSS
Cite this brief
Drug Landscape (2026). anti-CCR2 monoclonal antibody MLN1202 — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-ccr2-monoclonal-antibody-mln1202. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab